# Anticancer Mechanisms
Aspirin is mechanistically unusual because it does not depend on one pathway alone.
Its anticancer relevance appears to come from several overlapping effects. That breadth is one reason it remains a credible repurposing candidate.
### Special report
{% hint style="info" %}
#### Featured deep dive
[**Aspirin and Thromboxane A2 (TXA2)**](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md) explains one of aspirin's most important anti-metastatic mechanisms.
It covers platelet shielding, immune evasion, the **TXA2 → ARHGEF1 → CD8+ T-cell** axis, and how to judge when platelet or TXA2 biology is likely to matter in a real patient.
{% endhint %}
### Primary mechanisms
#### 1. COX inhibition
* inhibits **COX-1** and **COX-2**
* reduces prostaglandin-driven inflammation
* may weaken tumour growth, angiogenesis, and immune evasion
#### 2. Platelet-mediated metastasis suppression
* reduces platelet activation through [**thromboxane A2**](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md) suppression
* weakens platelet shielding of circulating tumour cells
* may reduce metastatic seeding
#### 3. Immune surveillance support
* may improve tumour antigen presentation
* may reduce immune suppression within the tumour microenvironment
* supports immunotherapy-combination interest
#### 4. p53 and cell-cycle effects
* may activate **p53-related** pathways in some models
* may increase growth arrest and apoptosis signals
* may work alongside broader cell-cycle control effects
#### 5. DNA repair and genomic-stability effects
* affects proteins linked to replication stress and repair
* may improve net genomic control in selected settings
* remains more mechanistic than clinically established
#### 6. PI3K-pathway relevance in colorectal cancer
* may preferentially benefit **PIK3CA**-altered colorectal cancer
* likely matters through downstream inflammatory and survival signalling linked to the **PI3K / AKT / mTOR** pathway
* now has prospective clinical support in biomarker-selected CRC
See [**Colorectal Cancer**](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/colorectal-cancer.md) for the fuller clinical context.
#### 7. Wnt / β-catenin and inflammatory pathway modulation
* may suppress **β-catenin / TCF** signalling
* may reduce **IL-6 / STAT3** inflammatory pressure
* gives aspirin broader gastrointestinal-oncology relevance
#### 8. Epigenetic and microRNA effects
* may influence histone-related regulation
* may activate tumour-suppressive microRNA programs
* could matter in **p53-deficient** settings
#### 9. Anti-angiogenic effects
* may reduce tumour-supporting vascular signalling
* appears relevant in some colon and haematologic models
* this mechanism is supportive, not the main story
### Practical interpretation
Aspirin's strength is its breadth.
It targets inflammation, immune escape, platelet-assisted metastasis, and tumour signalling at the same time.
Its most practice-relevant mechanism today is the **PI3K-pathway** signal in selected colorectal cancer.
That still does not make aspirin a proven general cancer therapy. It does make aspirin more than a broad anti-inflammatory hypothesis.
### Key References
* Thun MJ et al. (2014). Molecular targets of aspirin and cancer prevention (COX-dependent and independent pathways, protein acetylation). British Journal of Cancer 111(1):61–67. [https://www.nature.com/articles/bjc2014271\[^8\]](https://www.nature.com/articles/bjc2014271\[%5E8])
* Piazza GA et al. (2013). COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Frontiers in Oncology 3:181. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3708159/\[^9\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC3708159/\[%5E9])
* Ng K et al. (2024). Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Perspectives (COX-2 inhibition, TIGIT suppression, ER stress, apoptosis). Pharmaceutics 17(2):225. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11866938/\[^10\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC11866938/\[%5E10])
* Pathi S et al. (2023). Aspirin and the metabolic hallmark of cancer (Wnt, NF-κB, mTOR/HIF-1α targeting). Exploration of Targeted Anti-tumor Therapy 4(5). [https://www.explorationpub.com/Journals/etat/Article/1002155\[^11\]](https://www.explorationpub.com/Journals/etat/Article/1002155\[%5E11])
* Stark LA et al. (2017). Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus. Biomedicines 5(3):43. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5618301/\[^12\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC5618301/\[%5E12])
* Turini ME & DuBois RN (2006). Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a COX-independent mechanism. FASEB J 20(12):2009–16. [https://pubmed.ncbi.nlm.nih.gov/17012253/\[^13\]](https://pubmed.ncbi.nlm.nih.gov/17012253/\[%5E13])
* Deng L et al. (2024). Exploring Aspirin's Potential in Cancer Prevention (COX-1/2 inhibition, PI3K/AKT, ERK pathways, apoptosis induction). Biomolecules 14(10):1320. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11498354/\[^14\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC11498354/\[%5E14])
Ricci F et al. (2012). Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. ISRN Oncology 2012:260705. [https://pmc.ncbi.nlm.nih.gov/articles/PMC3816673/\[^15\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC3816673/\[%5E15])
Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?
Feedback Form
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.